TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32040868
Drug: Doxepin cream
Normalized name: doxepin Topical Cream
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin cream (5%) for 7 days
Study: 32040868
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream for 7 days
Study: 33684953
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of metformin SR 1000 mg and 1 tablet of TQ 50 mg once daily (T1)
Study: 33684953
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of metformin SR 1000 mg and 2 tablets of TQ 50 mg once daily (T2)
Study: 33684953
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of metformin SR 1000 mg only (R)
Study: 32027810
Drug: Ultra-low dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low dosage of rituximab (200 mg single infusion)
Study: 35333885
Drug: Vitamin D3-fortified
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3-fortified fruit juices containing 4000 IU (100 mcg) daily for 8 weeks
Study: 35333885
Drug: Placebo-fruit juices
Normalized name: Morinda citrifolia fruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-fruit juices daily for 8 weeks
Study: 36288843
Drug: Dry needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry needling (DN) intervention, performed thrice a week for 2 weeks, in addition to conventional treatment
Study: 36288843
Drug: Conventional treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment, performed once a day for 40 min, five times a week for 2 weeks
Study: 33333459
Drug: Clinical decision
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical decision support alert for carbohydrate-containing medication orders
Study: 35435565
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning models for predicting resistance to somatostatin receptor ligands (SRL)
Study: 33830998
Drug: 850 mg
Normalized name: bran 850 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 850 mg metformin three times daily
Study: 35750726
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education (Group I)
Study: 34845600
Drug: Lactocare® (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactocare® (two times daily for 12 weeks)
Study: 34845600
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two times daily for 12 weeks)
Study: 33179818
Drug: Pump therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump therapy with continuous glucose monitoring offering low glucose suspend (LGS)
Study: 34843843
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) treatment with 30 pre- and 10 postoperative exposures at 243 kPa for 90 min each
Study: 32920607
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide gel (Opalescence, Ultradent Products) (2 h/day, for 14 days)
Study: 32920607
Drug: 40% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% hydrogen peroxide gel (Opalescence Boost, Ultradent Products) (three bleaching sessions, once a week, 45 min/session)
Study: 36331921
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo treatment
Study: 35461522
Drug: All chimeric
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All chimeric vaccines
Study: 36494245
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (Group T)
Study: 32087032
Drug: Oral bacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bacterial lysate (heat-killed Escherichia coli and Enterococcus faecalis)
Study: 36156542
Drug: Glucosamine and
Normalized name: Glucosamine and Chondroitin Complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine and chondroitin sulfate supplementation for 4 weeks in addition to manual therapy and resistance exercise training.
Study: 36156542
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and resistance exercise training.
Study: 32306797
Drug: Triple therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy: aspirin+prasugrel/ticagrelor+vorapaxar
Study: 32306797
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (drop aspirin): prasugrel/ticagrelor+vorapaxar
Study: 32306797
Drug: DAPT: aspirin+prasugrel/ticagrelor
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT: aspirin+prasugrel/ticagrelor
Study: 34478926
Drug: Atosiban (6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (6.75 mg IV 30 min before embryo transfer, followed by 18 mg/h for 1 h, then 6 mg/h for 2 h)
Study: 32870042
Drug: Autologous Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Protein Solution (APS) injection
Study: 33184453
Drug: Iodine status
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine status (UI/Cr <150 µg/g)
Study: 37753718
Drug: Etripamil nasal
Normalized name: etripamil
DrugBank: Etripamil (DB12605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etripamil nasal spray
Study: 35551053
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) using a low-level GaAlAs diode laser (continuous wave of 810 nm wavelength, power of 200 mW, energy density of 12–14 J/cm2) for 12 sessions (2 times/week for 6 weeks)
Study: 33641621
Drug: Protect Your
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protect Your Family intervention administered by lay healthcare workers
Study: 32380509
Drug: Acid-suppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-suppressive therapy + feeding bundle
Study: 32380509
Drug: Acid-suppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-suppressive therapy only (conventional)
Study: 33064895
Drug: New metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: New metformin users with depression
Study: 33064895
Drug: New metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: New metformin users without depression (controls)
Study: 35732505
Drug: Superficial Acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial Acupuncture (SA) group, same sessions and treatment frequency as TA, avoiding deqi sensation.
Study: 36442467
Drug: Early feeding
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early feeding group (1 day of trophic feeding at 20-24 mL/kg/day)
Study: 36442467
Drug: Late feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late feeding group (4 days of trophic feeding at 20-24 mL/kg/day)
Study: 33526496
Drug: Describing side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Describing side effects as a sign treatment is working
Study: 35315017
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (nifedipine, nicardipine)
Study: 34476447
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral health education after treatments
Study: 34476447
Drug: Clinical education
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical education at the time of treatments
Study: 33312712
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT), low-energy intervention group, treated once a week for 10 weeks.
Study: 32690105
Drug: NEON Intervention
Normalized name: neon
DrugBank: Neon (DB11589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEON Intervention (treatment as usual plus immediate access to the NEON Intervention for 1 year)
Study: 32690105
Drug: Cost-effectiveness analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-effectiveness analysis using EQ‐5D‐5 L and Client Service Receipt Inventory data
Study: 32690105
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus access to the NEON Intervention after 1 year
Study: 35985418
Drug: 12-month home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month home-based physical exercise (supervised by physiotherapist, 60 minutes, twice a week)
Study: 34938893
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium oxide (MgOx)
Study: 34938893
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium citrate (MgCit)
Study: 35181385
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP) nasal spray
Study: 34314511
Drug: PCV13 (13-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 (13-valent pneumococcal conjugate vaccines)
Study: 34314511
Drug: Diphtheria toxoid
Normalized name: diphtheria toxoid
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria toxoid and tetanus toxoid vaccine
Study: 33499887
Drug: Prednisone 40
Normalized name: prednisone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 40 mg days 1 to 4, then 20 mg days 5 to 8
Study: 32891139
Drug: Weekly vitamin
Normalized name: Ezy Dose Weekly Vitamin Planner 2XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly vitamin D2 50,000 IU
Study: 32891139
Drug: Weekly vitamin
Normalized name: Ezy Dose Weekly Vitamin Planner 2XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly vitamin D2 2500 IU
Study: 32816890
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg twice daily) and Pembrolizumab (2 mg/kg every 3 weeks)
Study: 32569429
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% capsaicin cream
Study: 36394475
Drug: Regular low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Regular low-dose sustained-release morphine (0/8/16/24 mg every 24 hours)
Study: 34187862
Drug: Home medication
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home medication
Study: 34187862
Drug: Nonhome medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonhome medication
Study: 37099968
Drug: ADT +
Normalized name: Antidepressant+
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT + brexpiprazole 2-3 mg/day
Study: 35658908
Drug: Deep Learning
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep Learning Image Reconstruction (DLIR) - Low intensity (L)
Study: 32885419
Drug: Okara soup
Normalized name: MALT SOUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Okara soup (4.1 g fiber/meal)
Study: 32885419
Drug: Placebo (soymilk,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (soymilk, 0.1 g fiber/meal)
Study: 35610666
Drug: GeneXpert® point‐of‐care
Approvals — FDA: no, EMA: no, PMDA: no
Description: GeneXpert® point‐of‐care diagnostic testing for Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis, with same‐day treatment for detected infection(s). Arm 1 will additionally receive a test‐of‐cure 3 weeks post‐treatment, while Arm 2 will receive a repeat test at 30‐34 weeks' gestation.
Study: 36099496
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac (NSAID) 50 mg
Study: 36099496
Drug: Both pancreatic
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both pancreatic stent placement and rectal NSAIDs (PS + NSAID)
Study: 33629812
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg day-1 xanthohumol for eight weeks
Study: 32862830
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of RBX2660 via enema
Study: 32862830
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of RBX2660 via enema
Study: 32875946
Drug: Potassium hydroxide
Normalized name: Potassium Hydroxide
DrugBank: Potassium hydroxide (DB11153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium hydroxide 5% solution (KOH)
Study: 32875946
Drug: 5-fluorouracil cream
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil cream (5-FU)
Study: 32054509
Drug: 4-week oral
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week oral Phe administration
Study: 32054509
Drug: 4-week placebo
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week placebo administration
Study: 36235623
Drug: Alpha-Glycerylphosphorylcholine (A-GPC)
Normalized name: glycerylphosphorylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-Glycerylphosphorylcholine (A-GPC) 1000 mg
Study: 32530769
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus FU (60 mg/m2 on day 1 and 1,000 mg/m2 on days 1-4 every 21 days for 24 weeks)
Study: 32530769
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus paclitaxel (AUC 5 on day 1 and 80 mg/m2 on days 1, 8, and 15 every 28 days for 24 weeks)
Study: 35459000
Drug: Vibrotactile sensory
Normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vibrotactile sensory augmentation (SA)
Study: 34529887
Drug: Multimodal preemptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal preemptive analgesia (flurbiprofen axetil and oxycodone before skin incision combined with bilateral transverse abdominis plane block)
Study: 32558314
Drug: Antimicrobial peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial peptide KSL‐W formulated as an antiplaque chewing gum (APCG), 30 mg, administered three times per day for four days
Study: 33787834
Drug: Revacept 80
Normalized name: Revacept
DrugBank: PR-15 (DB06037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revacept 80 mg
Study: 35526272
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose adalimumab regimen
Study: 33004464
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 and 25 mg)
Study: 36435427
Drug: AI-optimized weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI-optimized weekly interventions (combination of expert-led group, expert-led call, paraprofessional-led call, and automated message)
Study: 36435427
Drug: Gold standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold standard condition (12 months of weekly BWL groups)
Study: 32811637
Drug: Fixed-dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose of nine sessions of MET/CBT
Study: 32811637
Drug: PRN condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN condition with smaller initial dose of treatment
Study: 32811637
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (MET/CBT and PRN)
Study: 34714961
Drug: Point-by-point technique
Normalized name: APPLICATOR POINTED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-by-point technique injection
Study: 34628065
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg subcutaneously every 2 weeks for 24 weeks
Study: 34805810
Drug: PB-201 50+50
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-201 50+50 mg
Study: 34805810
Drug: PB-201 100+50
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-201 100+50 mg
Study: 34805810
Drug: PB-201 100+100
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-201 100+100 mg
Study: 33013035
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane (ESP) block with 0.2% ropivacaine (0.2 ml/kg on either side)
Study: 33013035
Drug: Transversus abdominis
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus abdominis plane (TAP) block with 0.2% ropivacaine (0.2 ml/kg on either side)
Study: 32516497
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of home-use microneedle device and 5% minoxidil solution
Study: 32516497
Drug: 5% minoxidil
Normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% minoxidil topical solution only
Study: 34861168
Drug: ianalumab 5
Normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ianalumab 5 mg
Study: 34861168
Drug: ianalumab 50
Normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ianalumab 50 mg
Study: 34861168
Drug: ianalumab 300
Normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ianalumab 300 mg
Study: 35623816
Drug: Stevia (15.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stevia (15.3 mg)
Study: 35623816
Drug: d-tagatose (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-tagatose (5000 mg)
Study: 35623816
Drug: Control (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (60 mL water)
Study: 33610836
Drug: ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranibizumab (0.5 mg/50 μl)
Study: 33610836
Drug: aflibercept (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: aflibercept (2.0 mg/50 μl)
Study: 33610836
Drug: bevacizumab (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: bevacizumab (1.25 mg/50 μl)
Study: 33677048
Drug: Involved-field irradiation
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved-field irradiation with definitive chemoradiation therapy (61.2 Gy in 34 fractions using intensity modulated radiation therapy)
Study: 33677048
Drug: Involved-field irradiation
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved-field irradiation with definitive chemoradiation therapy
Study: 36030811
Drug: Telemedicine group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine group (asynchronous online consultation, 200 mg mifepristone and 800 μg misoprostol at home)
Study: 36030811
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care group (in-person consultation, 200 mg mifepristone in clinic and 800 μg misoprostol at home)
Study: 36045818
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg of rectal misoprostol
Study: 35666231
Drug: SDX/d-MPH 26.1/5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDX/d-MPH 26.1/5.2 mg (Treatment A)
Study: 35666231
Drug: SDX/d-MPH 39.2/7.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDX/d-MPH 39.2/7.8 mg (Treatment B)
Study: 35666231
Drug: SDX/d-MPH 52.3/10.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDX/d-MPH 52.3/10.4 mg (Treatment C)
Study: 35666231
Drug: SDX/d-MPH 52.3/10.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDX/d-MPH 52.3/10.4 mg (multiple dosing)
Study: 33767064
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (specific types not mentioned)
Study: 33767064
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (empagliflozin)
Study: 35807922
Drug: Graded Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graded Protein (GP) diet (0.8 g/kg/d at week 1 to 2.2 g/kg/d at week 10 with whey protein supplement)
Study: 35807922
Drug: Constant Protein
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant Protein (CP) diet (0.8-1.0 g/kg/d with no protein supplement)
Study: 33715655
Drug: Spray-on 80%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray-on 80% Cu-20% Ni (spray-on)
Study: 33780463
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (n=253)
Study: 35475948
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust exposure (particle mass concentrations around 300 µg/m3)
Study: 35301888
Drug: rosuvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin monotherapy
Study: 35301888
Drug: rosuvastatin/ezetimibe combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin/ezetimibe combination therapy
Study: 34268884
Drug: Oral metformin
Normalized name: metformin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metformin (1 g) with codeine (25 mg)
Study: 34268884
Drug: Intravenous metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metformin (0.5 g) with codeine (25 mg)
Study: 34268884
Drug: Oral metformin
Normalized name: metformin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metformin (1 g) without codeine
Study: 34268884
Drug: Intravenous metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metformin (0.5 g) without codeine
Study: 34743319
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg daily for 7 days, then 20 mg daily for 7 days)
Study: 34743319
Drug: Placebo (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (14 days before psilocybin administration)
Study: 38326432
Drug: Psilocybin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (25 mg)
Study: 34423676
Drug: Brigatinib 180
Normalized name: brigatinib 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 180 mg once daily (with a 7-day lead-in at 90 mg once daily)